Candel Therapeutics, Inc. (CADL) Dividend History

Candel Therapeutics, Inc. (CADL) is a clinical-stage biopharmaceutical company focused on developing innovative immunotherapies for the treatment of cancer. The company leverages its proprietary oncolytic viral platform to design and develop therapies aimed at stimulating the immune system to recognize and destroy tumors, with a focus on translating these therapies into effective solutions for patients with various types of cancer.

117 Kendrick Street, Needham, MA, 02494
Phone: 617-916-5445
Website: https://www.candeltx.com

Dividend History

Candel Therapeutics, Inc. currently does not pay dividends

Company News

  • Candel Therapeutics published positive phase 1b clinical trial data on the combination of CAN-2409 and nivolumab plus standard of care in newly diagnosed high-grade glioma patients, demonstrating a promising safety profile and potential survival benefit.

    GlobeNewswire Inc.
  • Candel Therapeutics' Interim Chief Financial Officer Charles Schoch sold over $63,000 worth of company stock to cover tax withholding obligations related to the vesting of restricted stock units. The transaction indicates continued investment in the company's future.

    Investing.com
  • Candel (CADL) surges 431% in the year-to-date period, driven by positive developmental and regulatory updates from the clinical program for CAN-2409 across two different cancer indications.

    Zacks Investment Research
    Featured Companies: ALXO ANVS ENTX
  • Shares of Fastenal Company (NASDAQ: FAST) fell sharply during Thursday’s session following worse-than-expected first-quarter financial results. Fastenal reported first-quarter FY24 sales growth of 1.9% Y/Y to $1.895 billion, missing the consensus of $1.914 billion. The company's first-quarter EPS was 52 cents, missing the consensus of 53 cents. Fastenal shares dipped 6.7% to $69.73 on Thursday. Here are some other stocks moving in today's mid-day session. Gainers Rallybio Corporation (NASDAQ: RLYB) shares climbed 89.6% to $3.09 after the company announced a collaboration with Johnson & Johnson to advance therapeutics for pregnant individuals at risk of FNAIT. Rent the Runway, Inc. (NASDAQ: RENT) shares jumped 74.5% to $12.91 after the company reported mixed fourth-quarter financial results and issued guidance. Eliem Therapeutics, Inc. (NASDAQ: ELYM) jumped 59.6% to $4.2650. The company announced that it entered into a definitive acquisition agreement to acquire Tenet and it also entered into a securities purchase agreement for a $120 million private placement. Akanda Corp. (NASDAQ: AKAN) gained 36% to $0.1632. Akanda, last month, announced a plan to evaluate opportunities in Bitcoin, Blockchain and AI applications in the cannabis industry. Alpine Immune Sciences, Inc. (NASDAQ: ALPN) rose 36.6% to $64.25 after Vertex entered into an agreement to acquire the company. Candel Therapeutics, Inc. (NASDAQ: CADL) surged 29.6% to $6.61 after the company received FDA orphan drug designation for CAN-2409 for the treatment of pancreatic cancer. Enliven Therapeutics, Inc. (NASDAQ: ELVN) gained 26% to $24.97. Enliven Therapeutics announced proof ...

    Benzinga
Page data last updated 07/23/2025 16:46:22 UTC